Phillip J. Koo, MD, presented “Future Directions in Molecular and Multi-Modality Imaging and Theranostics of Prostate Cancer” during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in October 2020.
How to cite: Koo, Phillip J. “Future Directions in Molecular and Multi-Modality Imaging and Theranostics of Prostate Cancer” October 2020. Accessed Jul 2024. https://grandroundsinurology.com/future-directions-in-molecular-and-multi-modality-imaging-and-theranostics-of-prostate-cancer/
Future Directions in Molecular and Multi-Modality Imaging and Theranostics of Prostate Cancer – Summary
Phillip J. Koo, MD, Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona, discusses the clinical, research, and educational targets that will advance nuclear medicine’s future role in prostate cancer treatment. He proposes that physicians should consider nuclear medicine the fourth pillar of a cancer specialty, not only for its role in diagnostics but also due to the increased use of radiopharmaceuticals. Dr. Koo reviews results from the TheraP and VISION trials that illustrate the efficacy of PSMA PET/CT, the current diagnostic standard in clinical care. Dr. Koo then describes how nuclear medicine clinicians and radiologists can partner with medical oncologists in clinical settings to create patient-friendly, multidisciplinary care models. This model further integrates nuclear medicine clinicians and radiologists into diagnostic and therapeutic discussions, with the aim of determining the appropriate type of therapy faster. Relatedly, he sees an opportunity for nuclear medicine physicians to lead clinical trials as principal investigators. Dr. Koo concludes with a discussion about the role of education, contending that exposing medical students and residents to nuclear medicine is key to developing a future workforce.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian and his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System in Philadelphia, Pennsylvania. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM). His academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven motion correction. He has lectured nationally and internationally on topics related to imaging and radiopharmaceutical based therapies in prostate cancer. In 2022, Dr. Koo was the recipient of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award.
